We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Australian Scientist Wins Biochemistry Award

By Biotechdaily staff writers
Posted on 19 Jul 2004
The Analytic Biochemistry Prize for 2004, worth around U.S.$60,000, has been awarded to Prof. More...
Susan Clark, of Sydney (Australia,) for her pioneering work in molecular biology and epigenetics. The award was made by the German United Association for Clinical Chemistry and Laboratory Medicine (DGKL) for outstanding achievements in the fields of biochemical and molecular analytics, clinical chemistry, and molecular medicine. The prize was sponsored by Beckman Coulter (Fullerton, CA, USA).

Prof. Clark, head of the Epigenetics Unit at the Garvan Institute in Sydney, has been recognized for her outstanding research achievements in the field of DNA methylation analysis over the last 10 years. This includes the development of a revolutionary sequencing protocol that is now regarded internationally as the best method of detecting methylated cytosines in a DNA sequence. The detection of methylated DNA sequences in secretions and excretions as well as blood may make an important contribution to early diagnosis of tumors.

"This is quite different from gene mutation as a cause of cancer and potentially far more significant,” said Prof. Dr. Michael Oellerich, president of DGKL. "It appears she has found a way to accurately identify a process taking place in a gene where the inbuilt process of gene regulation is silenced or switched off. The body's natural control mechanism can then no longer function correctly.”

While early marker tests are now being researched for their functionality, Prof. Oellerich cautioned that this is still in its early stages. "If we can correctly identify methylation taking place within the gene before it causes damage, then we potentially have a radically new way of treating and detecting disease.”

The prize presentation was made on Sunday, June 27, 2004, at the Staudinger Symposium in Kloster Banz (Germany). Since the prize was first launched in 1970, the award has recognized the work of 27 world-renowned scientists, five of whom have subsequently won a Nobel Prize.




Related Links:
DGKL

New
Gold Member
Aspiration System
VACUSAFE
New
Gold Member
STI Test
Vivalytic MG, MH, UP/UU
New
Urine Analyzer
respons® UDS100
New
Electrolyte Analyzer
BKE-B
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image

Urine-Based Multi-Cancer Screening Test Receives FDA Breakthrough Device Designation

Early detection across multiple cancers remains a major unmet need in population screening. Non-invasive approaches that can be delivered at scale may broaden access and shift diagnoses to earlier stages.... Read more

Molecular Diagnostics

view channel
Image: The new approach focuses on CpG DNA methylation, a chemical modification of cytosine and guanine bases, using tumor samples to develop a computational model that distinguishes among 21 cancer types (photo credet: 123RF)

Machine Learning Model Uses DNA Methylation to Predict Tumor Origin in Cancers of Unknown Primary

Cancers of unknown primary (CUP) are metastatic malignancies in which the primary site cannot be identified, complicating treatment selection. Many patients consequently receive broad, nonspecific chemotherapy... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.